ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 95 filers reported holding ACLARIS THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.79 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $404,472 | -41.9% | 59,047 | -12.0% | 0.00% | 0.0% |
| Q2 2023 | $695,837 | +32.3% | 67,101 | +3.2% | 0.00% | 0.0% |
| Q1 2023 | $526,052 | -49.6% | 65,025 | -2.0% | 0.00% | -50.0% |
| Q4 2022 | $1,044,603 | +1.1% | 66,324 | +1.1% | 0.00% | 0.0% |
| Q3 2022 | $1,033,000 | +19.4% | 65,616 | +5.8% | 0.00% | +100.0% |
| Q2 2022 | $865,000 | -17.7% | 61,998 | +1.7% | 0.00% | 0.0% |
| Q1 2022 | $1,051,000 | +8.8% | 60,986 | -8.2% | 0.00% | 0.0% |
| Q4 2021 | $966,000 | -15.9% | 66,460 | +4.1% | 0.00% | 0.0% |
| Q3 2021 | $1,149,000 | +9.2% | 63,821 | +6.6% | 0.00% | 0.0% |
| Q2 2021 | $1,052,000 | +2046.9% | 59,896 | +26.5% | 0.00% | – |
| Q1 2020 | $49,000 | -44.3% | 47,336 | +1.2% | 0.00% | – |
| Q4 2019 | $88,000 | +72.5% | 46,787 | -1.4% | 0.00% | – |
| Q3 2019 | $51,000 | -51.0% | 47,440 | 0.0% | 0.00% | – |
| Q2 2019 | $104,000 | -68.7% | 47,440 | -14.4% | 0.00% | -100.0% |
| Q1 2019 | $332,000 | -19.0% | 55,413 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $410,000 | -31.0% | 55,413 | +35.5% | 0.00% | 0.0% |
| Q3 2018 | $594,000 | -27.3% | 40,904 | -0.0% | 0.00% | -50.0% |
| Q2 2018 | $817,000 | +32.2% | 40,907 | +16.0% | 0.00% | +100.0% |
| Q1 2018 | $618,000 | -31.6% | 35,264 | -3.8% | 0.00% | -50.0% |
| Q4 2017 | $904,000 | -2.9% | 36,645 | +1.6% | 0.00% | 0.0% |
| Q3 2017 | $931,000 | -3.8% | 36,058 | +1.0% | 0.00% | 0.0% |
| Q2 2017 | $968,000 | +46.2% | 35,696 | +60.8% | 0.00% | +100.0% |
| Q1 2017 | $662,000 | +4.7% | 22,196 | -4.7% | 0.00% | 0.0% |
| Q4 2016 | $632,000 | +22.7% | 23,296 | +15.9% | 0.00% | 0.0% |
| Q3 2016 | $515,000 | +47.6% | 20,096 | +6.4% | 0.00% | 0.0% |
| Q2 2016 | $349,000 | +51.1% | 18,896 | +54.7% | 0.00% | – |
| Q1 2016 | $231,000 | -19.5% | 12,213 | +14.7% | 0.00% | -100.0% |
| Q4 2015 | $287,000 | – | 10,650 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |